{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'c.', 'Requires hospitalisation or prolongation of an existing hospitalisation,', 'Note: In general, hospitalisation signifies that the subject has been admitted at the', 'hospital or emergency ward for observation and/or treatment that would not have', \"been appropriate in the physician's office or in an out-patient setting.\", 'Complications that occur during hospitalisation are also considered AEs. If a', 'complication prolongs hospitalisation or fulfils any other serious criteria, the event', 'will also be considered serious. When in doubt as to whether \"hospitalisation\\'', 'occurred or was necessary, the AE should be considered serious.', 'Hospitalisation for elective treatment of a pre-existing condition (known or', 'diagnosed prior to informed consent signature) that did not worsen from baseline is', 'NOT considered an SAE.', 'd.', 'Results in disability/incapacity,', \"Note: The term disability means a substantial disruption of a person's ability to\", 'conduct normal life functions. This definition is not intended to include experiences', 'of relatively minor medical significance such as uncomplicated headache, nausea,', 'vomiting, diarrhoea, influenza like illness, and accidental trauma (e.g., sprained', 'ankle) which may interfere or prevent everyday life functions but do not constitute a', 'substantial disruption.', 'or', 'e.', 'Is a congenital anomaly/birth defect in the offspring of a study subject', 'Medical or scientific judgement should be exercised in deciding whether reporting is', 'appropriate in other situations, such as important medical events that may not be', 'immediately life-threatening or result in death or hospitalisation but may jeopardise', 'the subject or may require medical or surgical intervention to prevent one of the', 'other outcomes listed in the above definition. These should also be considered', 'serious. Examples of such events are invasive or malignant cancers, intensive', 'treatment in an emergency room or at home for allergic bronchospasm, blood', 'dyscrasias or convulsions that do not result in hospitalisation.', '7.1.3.', 'Clinical laboratory parameters and other abnormal assessments', 'qualifying as AEs or SAEs', 'In absence of diagnosis, abnormal laboratory findings (e.g., clinical chemistry,', 'haematology, urinalysis) or other abnormal assessments that are judged by the', 'investigator to be clinically significant will be recorded as AEs or SAEs if they meet the', 'definition of an AE or an SAE (refer to Sections 7.1.1 and 7.1.2). Clinically significant', 'abnormal laboratory findings or other abnormal assessments that are present at baseline', 'and significantly worsen following the start of the study will also be reported as AEs or', 'SAEs. However, clinically significant abnormal laboratory findings or other abnormal', 'assessments that are associated with the disease being studied, unless judged by the', \"investigator as more severe than expected for the subject's condition, or that are present\", 'or detected at the start of the study and do not worsen, will not be reported as AEs or', 'SAEs.', '19-OCT-2018', '60', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'The investigator will exercise his or her medical and scientific judgement in deciding', 'whether an abnormal laboratory finding or other abnormal assessment is clinically', 'significant.', '7.2.', 'Detecting and recording AEs, SAEs', '7.2.1.', 'Time periods for detecting and recording AEs and SAEs', 'AEs and SAEs related to study participation will be collected and recorded from the time', 'of the first study visit until the subject is discharged from the study.', 'In order to fulfil international reporting obligations, SAEs that are related to study', 'participation (i.e., protocol-mandated procedures, invasive tests, a change from existing', 'therapy) will be collected and recorded from the time the subject consents to participate', 'in the study/study start until she/he is discharged from the study.', 'AEs leading to withdrawal from the study, will be collected and recorded from the time', 'of the first study visit until the subject is discharged from the study.', 'An overview of the protocol-required reporting periods for SAEs and AEs leading to', 'withdrawal is given in Table 10.', 'Table 10', 'Reporting period for SAE and AEs leading to withdrawal (Amended', '19 October 2018)', 'Study activity', 'Screening', 'Visit 1', 'Visit 2', 'Visit 3', 'AECOPD', 'Study', 'Visit', 'Visit', 'Conclusion', 'Pre-Month', 'M 0', 'M 6', 'M 12', 'Within 96', '0', 'hours of', 'onset', 'symptoms', 'AEs/SAEs', 'related to', 'study', 'participation*', 'AEs/SAEs', 'leading to', 'withdrawal', 'from the', 'study', '*Study participation: Specific procedures required by study participation.', '19-OCT-2018', '61', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']\n\n###\n\n", "completion": "END"}